Document is current
Any future updates will be listed below
-
Authors
Ivković, Vanja
Anandh, Urmila https://orcid.org/0000-0003-3298-8642
Bell, Samira https://orcid.org/0000-0001-9100-1575
Kronbichler, Andreas https://orcid.org/0000-0002-2945-2946
Soler, Maria Jose https://orcid.org/0000-0003-3621-0766
Bruchfeld, Annette https://orcid.org/0000-0002-9752-9941
- License Information
-
More Information
Article History
Accepted: 31 July 2025
First Online: 4 September 2025
Competing interests
: U.A. reports no competing interests; V.I. has received a Long-term Fellowship grant from the European Renal Association (ERA) and is an Editorial Board member of NDT; S.B. reports consultancy fees from AstraZeneca, Bayer and GSK; A.K. reports consulting fees from Amgen, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Delta4, GlaxoSmithKline, Novartis, Otsuka, Roche and Walden Biosciences, all outside of the submitted work. A.K. serves as an Associate Editor of Glomerular Diseases and an Editor of NDT. M.J.S. reports personal fees from NovoNordisk, Jansen, Mundipharma, AstraZeneca, Esteve, Fresenius, Ingelheim Lilly, Vifor and ICU, and grants and personal fees from Boehringer Ingelheim; A.B. received consultancy fees from Amgen, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Otsuka and Sobi and payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from AstraZeneca, Bayer, Boehringer Ingelheim, ChemoCentryx, CSL Vifor, Fresenius, GlaxoSmithKline and Otsuka; A.B. is an Editorial Board member of CKJ.
